Screener
Aclaris Therapeutics ACRS Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Aclaris Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's debt-to-equity?
- Aclaris Therapeutics (ACRS) reported debt-to-equity of 0× in Q2 2026.
- How has Aclaris Therapeutics's debt-to-equity changed year-over-year?
- Aclaris Therapeutics's debt-to-equity decreased by 17.8% year-over-year, from 0× to 0×.
- What is the long-term trend for Aclaris Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's debt-to-equity has grown at a -44.1% compound annual growth rate (CAGR), from 0.4× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Aclaris Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude